Evidence map›Paper›PMID 36177014›Full record

ArticleFrontiers in immunology2022

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections.

Suelen H Qassim, Mohammad R Hasan, Patrick Tang, Hiam Chemaitelly, Houssein H Ayoub, Hadi M Yassine, Hebah A Al-Khatib, Maria K Smatti, Hanan F Abdul-Rahim, Gheyath K Nasrallah and 14 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 3 countries.

Suelen H QassimInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Mohammad R HasanDepartment of Pathology, Sidra Medicine, Doha, Qatar.
Patrick TangDepartment of Pathology, Sidra Medicine, Doha, Qatar.
Hiam ChemaitellyInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Houssein H AyoubMathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
Hadi M YassineBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Hebah A Al-KhatibBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Maria K SmattiBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Hanan F Abdul-RahimDepartment of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Gheyath K NasrallahBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Mohamed Ghaith Al-KuwariStrategy Planning and Health Intelligence Primary Health Care Corporation, Doha, Qatar.
Abdullatif Al-KhalHamad Medical Corporation, Doha, Qatar.
Peter CoyleBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Imtiaz GillaniHamad Medical Corporation, Doha, Qatar.
Anvar Hassan KaleeckalHamad Medical Corporation, Doha, Qatar.
Riyazuddin Mohammad ShaikHamad Medical Corporation, Doha, Qatar.
Ali Nizar LatifHamad Medical Corporation, Doha, Qatar.
Einas Al-KuwariHamad Medical Corporation, Doha, Qatar.
Andrew JeremijenkoHamad Medical Corporation, Doha, Qatar.
Adeel A ButtDepartment of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, United States.
Roberto BertolliniMinistry of Public Health, Doha, Qatar.
Hamad Eid Al-RomaihiMinistry of Public Health, Doha, Qatar.
Mohamed H Al-ThaniMinistry of Public Health, Doha, Qatar.
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Hamad Medical Corporation · QAQatar University · QAMinistry of Public Health · QAWeill Cornell Medical College in Qatar · QAPrimary Health Care · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2021, Qatar experienced considerable incidence of SARS-CoV-2 infection that was dominated sequentially by the Alpha, Beta, and Delta variants. Using the cycle threshold (Ct) value of an RT-qPCR-positive test to proxy the inverse of infectiousness, we investigated infectiousness of SARS-CoV-2 infections by variant, age, sex, vaccination status, prior infection status, and reason for testing in a random sample of 18,355 RT-qPCR-genotyped infections. Regression analyses were conducted to estimate associations with the Ct value of RT-qPCR-positive tests. Compared to Beta infections, Alpha and Delta infections demonstrated 2.56 higher Ct cycles (95% CI: 2.35-2.78), and 4.92 fewer cycles (95% CI: 4.67- 5.16), respectively. The Ct value declined gradually with age and was especially high for children <10 years of age, signifying lower infectiousness in small children. Children <10 years of age had 2.18 higher Ct cycles (95% CI: 1.88-2.48) than those 10-19 years of age. Compared to unvaccinated individuals, the Ct value was higher among individuals who had received one or two vaccine doses, but the Ct value decreased gradually with time since the second-dose vaccination. Ct value was 2.07 cycles higher (95% CI: 1.42-2.72) for those with a prior infection than those without prior infection. The Ct value was lowest among individuals tested because of symptoms and was highest among individuals tested as a travel requirement. Delta was substantially more infectious than Beta. Prior immunity, whether due to vaccination or prior infection, is associated with lower infectiousness of breakthrough infections, but infectiousness increases gradually with time since the second-dose vaccination.

Indexed as

COVID-19SARS-CoV-2AdolescentChildHumansQatarVaccinationYoung Adultbreakthrough infectionCOVID-19epidemiologyimmunityPCRreinfectionSARS-CoV-2 variantvaccine

Identifiers

PMID36177014
PMCPMC9513583
OpenAlexW4295412571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.